Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
| Status: | Recruiting | 
|---|---|
| Conditions: | Hospital, Pulmonary | 
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other | 
| Healthy: | No | 
| Age Range: | Any | 
| Updated: | 4/21/2016 | 
| Start Date: | December 2015 | 
| End Date: | September 2016 | 
| Contact: | Robert Segal, MD, FACP | 
| Email: | rsegal@discoverylabs.com | 
| Phone: | 215-488-9450 | 
A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome
The primary objective of this study is to evaluate the safety and efficacy of lucinactant
for inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32
weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP)
for Resipiratory Distress Syndrome (RDS) compared to neonates receiving nCPAP alone.
			for inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32
weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP)
for Resipiratory Distress Syndrome (RDS) compared to neonates receiving nCPAP alone.
Inclusion Criteria:
1. Signed ICF from legally authorized representative
2. 26 to 32 completed weeks PMA
3. Successful implementation of controlled nCPAP within 90 minutes after birth
4. Spontaneous breathing
5. Chest radiograph consistent with RDS
6. Within the first 20 hours after birth, respiratory insufficiency requiring an nCPAP
of 5 to 6 cm H2O to maintain SpO2 of 90% to 95%, with an FiO2 of 0.25 to 0.45 that is
clinically indicated for at least 30 minutes. Transient (<10 minutes) FiO2 excursions
below 0.25 or above 0.45 do not reset the 30-minute requirement.
Exclusion Criteria:
1. A heart rate that cannot be stabilized above 100 beats per minute (bpm) within 5
minutes of birth
2. Recurrent episodes of apnea requiring positive pressure ventilation (PPV) using
inflating pressures above the set CPAP pressure administered manually or mechanically
through any patient interface
3. A 5 minute Apgar score < 5
4. Major congenital malformation(s), including and cranial/facial abnormalities that
preclude delivery of nCPAP via nasal prongs, diagnosed antenatally or immediately
after birth
5. Other diseases or conditions, including those potentially interfering with
cardiopulmonary function (eg, hydrops fetalis or congenital infection, such as
toxoplasmosis, rubella, cytomegalovirus, and herpes simplex [TORCH])
6. A known or suspected chromosomal abnormality or syndrome
7. Premature rupture of membranes (PROM) > 2 weeks
8. Evidence of hemodynamic instability requiring vasopressors or steroids for
hemodynamic support and/or presumed clinical sepsis
9. A need for intubation and/or mechanical ventilation at any time before enrollment
into the study
10. The administration (or plan for administration) of any the following:
- Another investigational agent or investigational medical device
- Administration of any other surfactant agent
- Steroid treatment (exposure before birth is acceptable; ie, antenatal steroids)
We found this trial at
    8
    sites
	
								Morristown, New Jersey 07960			
	
			
					Principal Investigator: John Ladino, MD
			
						
										Phone: 973-971-4212
					Click here to add this to my saved trials
	
									1720 2nd Ave S
Birmingham, Alabama 35233
	
			Birmingham, Alabama 35233
(205) 934-4011  
							
					Principal Investigator: Waldemar Carlo, MD
			
						
										Phone: 205-996-6452
					
		University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...  
  
  Click here to add this to my saved trials
	
								Miami, Florida 33124			
	
			(305) 284-2211
							
					Principal Investigator: Cristina Navarrete, MD
			
						
										Phone: 305-585-6527
					
		University of Miami A private research university with more than 15,000 students from around the...  
  
  Click here to add this to my saved trials
	
									2301 Erwin Rd
Durham, North Carolina 27710
	
			Durham, North Carolina 27710
919-684-8111
							
					Principal Investigator: Michael Cotten, MD
			
						
										Phone: 919-597-8692
					
		Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...  
  
  Click here to add this to my saved trials
	
									11234 Anderson St
Loma Linda, California 92354
	
			Loma Linda, California 92354
(909) 558-4000
							
					Principal Investigator: Yona Nicolau, MD
			
						
										Phone: 909-651-5002
					
		Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...  
  
  Click here to add this to my saved trials
	
								Newark, Delaware 19713			
	
			
					Principal Investigator: Michael Antunes, MD
			
						
										Phone: 302-733-2153
					Click here to add this to my saved trials
	
									9205 SW Barnes Rd
Portland, Oregon 97225
	
			Portland, Oregon 97225
(503) 216-1234
							
					Principal Investigator: Joseph W Kaempf, MD
			
						
										Phone: 503-216-4655
					
		Providence St. Vincent Medical Center Providence St. Vincent is renowned for its many centers of...  
  
  Click here to add this to my saved trials
	
								San Diego, California 92123			
	
			
					Principal Investigator: Anup Katheria, MD
			
						
										Phone: 858-939-4966
					Click here to add this to my saved trials